AU2020390430A1 - Immunogenic protein against gonococcal infection - Google Patents

Immunogenic protein against gonococcal infection Download PDF

Info

Publication number
AU2020390430A1
AU2020390430A1 AU2020390430A AU2020390430A AU2020390430A1 AU 2020390430 A1 AU2020390430 A1 AU 2020390430A1 AU 2020390430 A AU2020390430 A AU 2020390430A AU 2020390430 A AU2020390430 A AU 2020390430A AU 2020390430 A1 AU2020390430 A1 AU 2020390430A1
Authority
AU
Australia
Prior art keywords
nhba
gonorrhoeae
subject
protein
neisseria
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
AU2020390430A
Other languages
English (en)
Inventor
Kate SEIB
Evgeny SEMCHENKO
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Griffith University
Original Assignee
Griffith University
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from AU2019904450A external-priority patent/AU2019904450A0/en
Application filed by Griffith University filed Critical Griffith University
Publication of AU2020390430A1 publication Critical patent/AU2020390430A1/en
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
    • C07K14/22—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Neisseriaceae (F)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A61K39/095—Neisseria
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/12—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from bacteria
    • C07K16/1203—Gram-negative bacteria
    • C07K16/1217—Neisseriaceae (F)
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/569—Immunoassay; Biospecific binding assay; Materials therefor for microorganisms, e.g. protozoa, bacteria, viruses
    • G01N33/56911—Bacteria
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/569—Immunoassay; Biospecific binding assay; Materials therefor for microorganisms, e.g. protozoa, bacteria, viruses
    • G01N33/571—Immunoassay; Biospecific binding assay; Materials therefor for microorganisms, e.g. protozoa, bacteria, viruses for venereal disease, e.g. syphilis, gonorrhoea
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55505—Inorganic adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55566—Emulsions, e.g. Freund's adjuvant, MF59
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/195—Assays involving biological materials from specific organisms or of a specific nature from bacteria
    • G01N2333/22—Assays involving biological materials from specific organisms or of a specific nature from bacteria from Neisseriaceae (F), e.g. Acinetobacter

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Molecular Biology (AREA)
  • Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • Urology & Nephrology (AREA)
  • Biomedical Technology (AREA)
  • Hematology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Microbiology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Analytical Chemistry (AREA)
  • Biotechnology (AREA)
  • Cell Biology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Virology (AREA)
  • Food Science & Technology (AREA)
  • Physics & Mathematics (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Epidemiology (AREA)
  • Mycology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Peptides Or Proteins (AREA)
AU2020390430A 2019-11-25 2020-11-20 Immunogenic protein against gonococcal infection Pending AU2020390430A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
AU2019904450A AU2019904450A0 (en) 2019-11-25 Immunogenic protein against gonococcal infection
AU2019904450 2019-11-25
PCT/AU2020/051257 WO2021102505A1 (en) 2019-11-25 2020-11-20 Immunogenic protein against gonococcal infection

Publications (1)

Publication Number Publication Date
AU2020390430A1 true AU2020390430A1 (en) 2022-07-14

Family

ID=76128579

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2020390430A Pending AU2020390430A1 (en) 2019-11-25 2020-11-20 Immunogenic protein against gonococcal infection

Country Status (10)

Country Link
US (1) US12479892B2 (https=)
EP (1) EP4065595A4 (https=)
JP (2) JP7825273B2 (https=)
KR (1) KR20220152402A (https=)
CN (1) CN115348968A (https=)
AU (1) AU2020390430A1 (https=)
BR (1) BR112022010167A2 (https=)
CA (1) CA3162559A1 (https=)
MX (1) MX2022006299A (https=)
WO (1) WO2021102505A1 (https=)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MX2023004729A (es) * 2020-10-23 2023-06-29 Omvax Inc Composiciones y metodos de vacunacion contra neisseria gonorrhoeae.
JP2024526293A (ja) * 2021-07-05 2024-07-17 エヴァクシオン・バイオテック・アクティエセルスカブ 淋菌を標的とするワクチン
WO2025196270A1 (en) 2024-03-22 2025-09-25 Limmatech Biologics Ag Outer membrane vesicle vaccines for the prevention of n. gonorrhoeae and methods of making and using thereof

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5047238A (en) 1983-06-15 1991-09-10 American Home Products Corporation Adjuvants for vaccines
GB8607679D0 (en) 1986-03-27 1986-04-30 Winter G P Recombinant dna product
US5091513A (en) 1987-05-21 1992-02-25 Creative Biomolecules, Inc. Biosynthetic antibody binding sites
US5811105A (en) 1987-12-23 1998-09-22 Glaxo Wellcome, Inc. Vaccines containing bacteria attenuated by mutations in two genes of the aromatic amino acid biosynthetic pathway
US5785973A (en) 1988-02-01 1998-07-28 Praxis Biologics, Inc. Synthetic peptides representing a T-cell epitope as a carrier molecule for conjugate vaccines
GB8912330D0 (en) 1989-05-30 1989-07-12 Wellcome Found Live vaccines
GB9007194D0 (en) 1990-03-30 1990-05-30 Wellcome Found Live vaccines
AUPO007396A0 (en) 1996-05-24 1996-06-20 Csl Limited Ebv ctl epitopes
AUPO784197A0 (en) 1997-07-10 1997-08-07 Csl Limited Treatment of nasopharyngeal carcinoma
EP2261338A3 (en) * 1998-05-01 2012-01-04 Novartis Vaccines and Diagnostics, Inc. Neisseria meningitidis antigens and compositions
NZ521531A (en) * 2000-02-28 2005-12-23 Chiron S Heterologous expression of neisserial proteins
EP1962961B1 (en) 2005-11-29 2013-01-09 The University Of Sydney Demibodies: dimerisation-activated therapeutic agents
JP6687597B2 (ja) * 2014-07-17 2020-04-22 グラクソスミスクライン バイオロジカルズ ソシエテ アノニム 髄膜炎菌ワクチン
MX2017015404A (es) * 2015-06-02 2018-05-22 De Staat Der Nederlanden Vert Door De Mini Van Vws Miniie Van Volksgezondheid Welzijn En Sport Visualizacion de superficie de antigenos en vesiculas de membrana externa gram-negativas.
CN106606775A (zh) 2015-10-27 2017-05-03 格里菲斯大学 脂质体a群链球菌疫苗
US12109259B2 (en) * 2016-09-02 2024-10-08 Glaxosmithkline Biologicals Sa Vaccines for Neisseria gonorrhoeae

Also Published As

Publication number Publication date
EP4065595A4 (en) 2023-12-20
EP4065595A1 (en) 2022-10-05
US20230181709A1 (en) 2023-06-15
KR20220152402A (ko) 2022-11-15
JP2023503963A (ja) 2023-02-01
US12479892B2 (en) 2025-11-25
CN115348968A (zh) 2022-11-15
MX2022006299A (es) 2023-01-19
JP7825273B2 (ja) 2026-03-06
BR112022010167A2 (pt) 2022-08-09
JP2026021348A (ja) 2026-02-10
CA3162559A1 (en) 2021-06-03
WO2021102505A1 (en) 2021-06-03

Similar Documents

Publication Publication Date Title
EP2265640B1 (en) Chimeric factor h binding proteins (fhbp) containing a heterologous b domain and methods of use
JP5622344B2 (ja) Ｎｅｉｓｓｅｒｉａ配合組成物
CN102834410B (zh) 改性的h因子结合蛋白（fhbp）及其使用方法
CA2452836C (en) Meningococcus adhesins nada, app and orf 40
EP3366696A1 (en) Vaccine
JP2026021348A (ja) 淋菌感染症に対する免疫原性タンパク質
AU2014296027A1 (en) Non-naturally occurring factor H binding proteins (fHbp) and methods of use thereof
WO2015123728A1 (en) Mycoplasma surface proteins and uses thereof
CN103687613A (zh) 蛋白f-具有层粘连蛋白和玻连蛋白结合性能的新的流感嗜血杆菌粘附素
EP1572729B1 (en) Mutant frpb protein and refolding method
US20110262476A1 (en) Mutant bacterial glycoproteins and uses thereof
AU2011284809B2 (en) Recombinant Neisseria meningitidis Por A porin proteins.
US20140341895A1 (en) PSEUDOMONAS AERUGINOSA OprM EPITOPES FOR USE IN DIAGNOSTICS AND THERAPEUTICS
HK1186476A (en) Recombinant neisseria meningitidis por a porin proteins
Ispasanie Immune responses to prototype GMMA vaccine against Neisseria meningitidis in Africa
HK1179980A (en) Factor h binding proteins (fhbp) with altered properties and methods of use thereof
HK1179980B (en) Factor h binding proteins (fhbp) with altered properties and methods of use thereof

Legal Events

Date Code Title Description
DA3 Amendments made section 104

Free format text: THE NATURE OF THE AMENDMENT IS: AMEND THE NAME OF THE INVENTOR TO READ SEIB, KATE AND SEMCHENKO, EVGENY